Finding Relief After Years of Unbearable Pain from Sickle Cell Disease: Allan's Story
Allan Byamukama was one of the first 15 people in the world to receive a cutting-edge gene therapy for sickle cell disease.
29th Annual Summer Course:
Current Techniques in Molecular Genetics 2019
Monday, July 15 through Friday, July 26
Massachusetts General Hospital, Main Campus, 55 Fruit Street
O'Keefe Auditorium
Hans-Christian Reinecker, Course Director
Dietary control of stem cells in physiology and disease
Omer Yilmaz | Monday, July 15 | 8:30 am |
Gut-liver-brain physiomimetics for the multimic studies of acute and chronic inflammation
Martin Trapecar | Monday, July 15 | 9:30 am |
Single-cell genomic approaches for understanding human barrier tissue dysfunction
Jose Ordovas-Montanes | Wednesday, July 17 | 8:30 am |
Detection of protein expression by immnocytochemistry
Sylvie Breton | Wednesday, July 17 | 9:30 am |
Gene discovery
Mark Daly | Friday, July 19 | 8:30 am |
Understanding human health and disease at the single-cell level
Orr Ashenberg | Friday, July 19 | 9:30 am |
Improving efficiency of CRISPR/Cas9-mediated genome editing in mice
Lin Wu | Monday, July 22 | 8:30 am |
Structure, function and detection of noncoding RNAs
Alan Mullen | Monday, July 22 | 9:30 am |
Advances in CRISPR genome editing for the modeling and treatment of disease
Benjamin Kleinstiver | Wednesday, July 24 | 8:30 am |
Epigenetics 101: Basic theory and lab techniques
Kate Jeffrey | Wednesday, July 24 | 9:30 am |
Multi'omics for the human microbiome
Curtis Huttenhower | Friday, July 26 | 8:30 am |
Towards the treatment of inflammatory bowel disease via rational manipulation of the gut microbiome
Brantley Hall | Friday, July 26 | 9:30 am |
Allan Byamukama was one of the first 15 people in the world to receive a cutting-edge gene therapy for sickle cell disease.
Mass General Brigham researchers say both types of artificial intelligence (AI) tools have potential to augment one another to better inform treatment decisions.
Physician-scientists at Massachusetts General Hospital are leading a clinical trial assessing the effectiveness of cell therapy to reinforce weakened tissue associated with fecal incontinence.
Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes.
Myocarditis is driven by a different immune response than the anti-tumor one, suggesting that the serious complication could one day be managed without halting cancer therapy.
Read how proton therapy saved the life of 19-year-old Chris Kobos after he was diagnosed with a rare chordoma.